Autologous Car123 T Lymphocytes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Institute of Hematology and Blood Transfusion, Czech RepublicCell therapyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Precursor Cell Lymphoblastic Leukemia-Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE CAMC Health System | Phase 4 | BB |
DEXAMETHASONE Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | B |
Cyclophosphamide Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | B |
ETOPOSIDE Asan Medical Center | Phase 2 | B |
DARATUMUMAB Janssen Research & Development, LLC | Phase 2 | B |
View all 33 →
Same molecule, other indications
Autologous Car123 T Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →